Financial Performance - For the year ended December 31, 2025, total revenues reached $11,374,996, while gross profit was $5,121,541[35]. - The net loss for the year ended December 31, 2025, was $5,814,867, compared to a net loss of $273,413 for the year ended December 31, 2024[35]. - For the fiscal year ended December 31, 2023, the company's total revenues were $19,433,945, a decrease from $15,864,773 in 2024 and $11,374,996 in 2025[45]. - The net loss for the year ended December 31, 2023, was $(11,307,239), compared to $(273,413) in 2024 and $(5,814,867) in 2025, indicating a significant increase in losses[45]. - The company reported a gross profit of $8,512,192 for the year ended December 31, 2023, after costs of revenue amounting to $(10,921,753)[36]. - In 2025, the company's revenues were $11,374,996, a decrease from $15,864,773 in 2024 and $19,433,945 in 2023, indicating a downward trend in financial performance[60]. - The company reported net losses of $(5,814,867) in 2025, $(273,413) in 2024, and $(11,307,239) in 2023, highlighting ongoing financial challenges[60]. Cash Transfers and Dividends - Zhongchao Cayman made cash transfers of $3.4 million, $4.4 million, and $0.1 million to Zhongchao USA for the years ended December 31, 2025, 2024, and 2023 respectively[25]. - No dividends or distributions were made to Zhongchao Cayman or U.S. investors for the years ended December 31, 2025, 2024, and 2023[25]. - The company intends to reinvest future earnings to finance the expansion of the PRC operating entities and does not anticipate paying cash dividends in the foreseeable future[26]. - The PRC government imposes a 10% withholding tax on dividends payable to non-PRC-resident enterprises, which may be reduced to 5% under certain conditions[154]. - The company has not applied for a tax resident certificate from the Hong Kong tax authority, which may affect its ability to enjoy a preferential withholding tax rate of 5%[32]. Regulatory Environment - PRC regulations require that dividends from indirect PRC subsidiaries can only be paid out of accumulated profits, and at least 10% of after-tax profits must be set aside for statutory reserves[28]. - The PRC government imposes controls on the conversion of RMB into foreign currencies, which may hinder the ability to remit dividends[29]. - The company is currently not required to obtain additional permissions from PRC authorities for its operations, but future regulatory changes could impose new requirements[24]. - The Trial Administrative Measures effective March 31, 2023, require domestic companies seeking to list overseas to fulfill filing procedures with the CSRC, which may impact future offerings[22]. - The PRC operating entities must comply with the Interim Administrative Measures on Overseas Securities Offering and Listing, which require filing procedures with the CSRC within three business days after each offering[147]. Operational Challenges - The company may face challenges in obtaining necessary government approvals for capital contributions or foreign loans to its PRC subsidiaries, which could adversely affect liquidity[32]. - The company faces intense competition in the healthcare information, education, and training services market, which is expected to persist and intensify[50]. - The company relies on a small number of major customers for a significant portion of its revenues, posing a risk to its financial stability[42]. - The company is actively seeking to recruit and retain IT talents and management personnel to support its growth and operational needs[47]. - The company intends to continue expanding its operations to pursue existing and potential market opportunities, despite facing significant management and operational challenges[48]. Risks and Liabilities - The VIE structure poses unique risks, including potential changes in PRC laws that could affect the company's operations and share value[21]. - The company may face significant legal liabilities if it fails to comply with evolving PRC data protection laws[188]. - The PRC operating entities may face costly intellectual property infringement claims, which could divert management's attention and require substantial damages or changes to their technology[77]. - The company currently lacks business interruption insurance, which could expose it to significant losses from unexpected events affecting its data facilities[70]. - The company may be subject to negative publicity and legal exposure due to security breaches or unauthorized access to data, which could harm its reputation and business[207]. Internal Controls and Compliance - The company has identified material weaknesses in its internal control over financial reporting, which could lead to inaccurate financial results or fraud[90]. - To address these weaknesses, the company has hired an experienced consultant and is providing ongoing training in U.S. GAAP to its personnel[92]. - The effectiveness of internal controls may vary over time due to inherent limitations, including human error and changes in conditions[93]. - The company is currently facing material weaknesses in internal controls over financial reporting, which could lead to inaccurate financial results and loss of investor confidence[94]. User Base and Market Position - The company has over 194,700 registered users and a database of approximately 111,070 healthcare experts, indicating a strong user base[44]. - In 2023, 52.5% of the company's revenues were derived from services and products provided to pharmaceutical enterprises, which decreased to 35.2% in 2024 and further to 32.5% in 2025, indicating a significant reliance on this sector[49]. - The company has expanded operations significantly, resulting in increased headcount and fixed overhead costs, which may impact profitability if resource utilization levels are not maintained[66]. Cybersecurity and Data Protection - The company has implemented security measures to protect customer and company data, but acknowledges potential vulnerabilities to cyber threats[205]. - The company may face uncertainties regarding compliance with evolving PRC cybersecurity laws and regulations, which could result in fines or operational disruptions[204]. - The latest Cybersecurity Review Measures require online platform operators with more than one million users' individual information to undergo a cybersecurity review before listing abroad[198]. - The PRC Data Security Law imposes obligations on entities regarding data security and privacy, with a national security review procedure for data activities that may affect national security[203]. Corporate Governance - The dual class structure of ordinary shares concentrates voting control with the CEO, limiting shareholder influence over corporate matters[114]. - The Company is classified as a "controlled company" under NASDAQ rules, which may exempt it from certain corporate governance requirements, potentially affecting shareholder protections[121]. - The CEO, Mr. Weiguang Yang, controls a majority of the voting power with 68,750 Class A and 624,972 Class B ordinary shares, allowing him to influence key decisions including mergers and director elections[120].

Core Viewpoint - Zhongchao Inc. announced a 1-for-8 share consolidation to regain compliance with Nasdaq Marketplace Rule 5550(a)(2) and maintain its listing on the Nasdaq Capital Market [1] Company Overview - Zhongchao Inc. is a platform-based internet technology company focused on providing services for patients with cancer and other major diseases [1] - The company is incorporated in the Cayman Islands and consolidates the financial results of its variable interest entity, Zhongchao Medical Technology (Shanghai) Limited, through contractual arrangements [1] Share Consolidation Details - The share consolidation will take effect on March 2, 2026, with Class A ordinary shares trading under the same symbol "ZCMD" but with a new CUSIP number of G9897X123 [1] - Every eight Class A ordinary shares will be consolidated into one Class A ordinary share, and the same applies to Class B ordinary shares [1] - Prior to the consolidation, the company had 25,754,124 Class A and 4,999,772 Class B ordinary shares outstanding, which will reduce to approximately 3,219,267 Class A and 624,972 Class B ordinary shares post-consolidation [1] Shareholder Impact - The share consolidation affects all shareholders uniformly and will not alter any shareholder's percentage interest in the company's outstanding ordinary shares, except for adjustments from fractional shares [1] - The consolidation was approved by the company's shareholders and board of directors on February 10, 2026 [1]

| 代码 | 名称 | 最新价 | 涨跌幅 ^ | 涨跌额 | 成交额 | | --- | --- | --- | --- | --- | --- | | ZCMD | 众巢医学 | 0.820 | -27.43% | -0.310 | 103.5万 | | LGCL | 周科任 | 0.1160 | -25.11% | -0.0389 | 189.38万 | | UPC | 大自然药业 | 7.220 | -23.68% | -2.240 | 326.25万 | | CLWT | 欧陆科仪 | 1.320 | -12.00% | -0.180 | 2.13万 | | ZYBT | 正业生物 | 2.720 | -11.69% | -0.360 | 97.44万 | 中概股收盘跌幅前五的个股为：众巢医学跌27.43%，罗科仕跌25.11%，大自然药业跌23.68%，欧陆科 仪跌12%，正业生物跌11.69%。(格隆汇) ...

Core Insights - Several biotech and healthcare stocks experienced significant after-hours gains on October 1, driven by technical momentum and recent clinical updates rather than new disclosures [1] Company Summaries - Zhongchao Inc. (ZCMD) saw a 14.04% increase in after-hours trading, rising to $1.30 from $1.14, despite no new filings or press releases [2] - AbCellera Biologics Inc. (ABCL) rose 11.41% in after-hours trading, closing at $6.64, following an 18.49% gain during the regular session, attributed to recent clinical trial progress [3][4] - Vor Biopharma Inc. (VOR) surged 9.53% in after-hours trading, recovering from a 19.42% drop during the regular session, with no new updates since a recent announcement regarding clinical data presentation [5] - Incannex Healthcare Inc. (IXHL) gained 6.48% in after-hours trading, partially recovering from a 6.94% drop, with the latest update showing positive Phase 2 trial results for PSX-001 [6] - Ovid Therapeutics Inc. (OVID) shares rose 8.03% in after-hours trading, building on a 5.38% gain during the regular session, with recent earnings report indicating a narrower net loss and higher revenue [7] - Bullfrog AI Holdings Inc. (BFRG) advanced 3.44% in after-hours trading, following a 3.57% rise during the regular session, after announcing an expansion of its sales and marketing team [8]

Revenue Performance - Total revenues for the six months ended June 30, 2025, were $5,601,079, a decrease of 32.7% compared to $8,348,329 for the same period in 2024[3] - Service revenues decreased to $4,910,889, down 25.6% from $6,595,083 in the prior year, while product revenues fell to $690,190, a decline of 60.7% from $1,753,246[3] Profitability - Gross profit for the six months ended June 30, 2025, was $2,709,724, representing a gross margin of 48.4%, compared to a gross profit of $4,737,096 and a margin of 56.7% in 2024[3] - The net loss attributable to Zhongchao Inc.'s shareholders for the six months ended June 30, 2025, was $965,254, compared to a net income of $90,047 in the same period of 2024[3] - The comprehensive loss attributable to Zhongchao Inc.'s shareholders for the six months ended June 30, 2025, was $591,928, compared to a loss of $366,974 in 2024[3] - Net loss for the six months ended June 30, 2025, was $862,319 compared to a net income of $182,933 for the same period in 2024[7] Operating Expenses - Operating expenses totaled $3,589,173, a decrease of 25.1% from $4,788,646 in the previous year, primarily due to reduced selling and marketing expenses[3] Cash and Assets - Cash and cash equivalents increased to $8,912,022 as of June 30, 2025, up 13.6% from $7,841,306 at the end of 2024[2] - Total current assets rose to $19,117,935, an increase of 2.2% from $18,707,217 as of December 31, 2024[2] - Cash and cash equivalents at the end of the period rose to $8,912,022 from $6,279,809 in the prior year[7] Liabilities - Total liabilities increased to $2,558,665, up 47.6% from $1,733,900 at the end of 2024[2] Shareholder Information - The weighted average number of ordinary shares outstanding for the six months ended June 30, 2025, was 25,388,903, compared to 2,637,340 in the prior year[3] Cash Flow and Investments - Net cash provided by operating activities increased to $1,820,881 from $809,598 year-over-year[7] - Net cash used in investing activities was $(980,271), compared to $(1,797,664) in the prior year[7] - Investments in short-term investments totaled $6,121,512, while proceeds from redemption of short-term investments were $5,241,241[7] Other Financial Metrics - Accounts receivable increased by $992,889, while accounts payable decreased by $396,025 compared to the previous year[7] - Cash paid for income tax increased to $89,807 from $67,043 year-over-year[7] - Depreciation and amortization expenses rose to $155,946 from $94,574 in the previous year[7] - Provision for expected credit losses was $291,227, up from $117,820 year-over-year[7] - The effect of exchange rate changes on cash and cash equivalents resulted in an increase of $230,106[7]

Core Insights - ZCMD's stock price increased by 21.72% to $1.05 per share, with a total market capitalization of $26.51 million as of August 26 [1] - The company's total revenue for the year ending December 31, 2024, is projected to be $15.86 million, representing an 18.37% year-over-year decline [1] - The net profit attributable to the parent company is expected to be -$0.6432 million, showing a significant improvement of 94.33% year-over-year [1] Company Overview - ZCMD is a Cayman Islands-registered holding company established on April 16, 2019, and operates through its subsidiary, ZCMD Medical Technology (Shanghai) Co., Ltd. [1] - The company focuses on medical education and patient education, offering three main business segments: 1. Medical MOOCs, 2. Sunshine Health Classroom, 3. Patient Assistance Program [1] - The Medical MOOCs platform combines advanced medical education concepts with modern internet technology, providing accessible and continuous learning opportunities for healthcare professionals [1]

Core Viewpoint - Zhongchao Medical (ZCMD) experienced an 11.25% increase in stock price, reaching $0.96 per share, with a total market capitalization of $24.23 million as of August 25 [1] Financial Performance - For the fiscal year ending December 31, 2024, Zhongchao Medical reported total revenue of $15.86 million, a year-over-year decrease of 18.37% [1] - The company recorded a net profit attributable to shareholders of -$0.6432 million, which represents a significant year-over-year increase of 94.33% [1] Company Overview - Zhongchao Medical was established on April 16, 2019, as an offshore holding company registered in the Cayman Islands, with its operations managed by its domestic subsidiary, Zhongchao Medical Technology (Shanghai) Co., Ltd. [1] - The company operates a digital medical education platform called Medical MOOC, which integrates advanced medical education concepts with modern internet technology, providing accessible and continuous learning opportunities for healthcare professionals [1] - Zhongchao Medical focuses on three main business segments: 1. Medical MOOC, 2. Sunshine Health Classroom, 3. Zhongxun Patient Assistance [1]

Core Insights - ZCMD's stock opened up by 5.44% on August 22, reaching $0.95 per share with a total market capitalization of $23.99 million [1] - For the fiscal year ending December 31, 2024, ZCMD reported total revenue of $15.86 million, a year-over-year decrease of 18.37%, while the net profit attributable to the parent company was -$0.6432 million, reflecting a year-over-year increase of 94.33% [1] Company Overview - ZCMD is a Cayman Islands-registered holding company established on April 16, 2019, and operates through its subsidiary, ZCMD Medical Technology (Shanghai) Co., Ltd [1] - The company offers a digital medical education platform called Medical MOOC, which integrates advanced medical education concepts with modern internet technology, providing accessible and continuous learning opportunities for healthcare professionals [1] - ZCMD focuses on three main business segments: 1. Medical MOOC, 2. Sunshine Health Classroom, 3. Patient Assistance Program [1]

Core Viewpoint - Zhongchao Medical (ZCMD) experienced a stock price increase of 2.44% on August 22, reaching $0.91 per share, with a total market capitalization of $22.99 million [1] Financial Performance - As of December 31, 2024, Zhongchao Medical reported total revenue of $15.86 million, a year-over-year decrease of 18.37% [1] - The company recorded a net profit attributable to shareholders of -$0.6432 million, which represents a year-over-year increase of 94.33% [1] Company Overview - Zhongchao Medical was established on April 16, 2019, as an offshore holding company registered in the Cayman Islands, operated by its domestic subsidiary, Zhongchao Medical Technology (Shanghai) Co., Ltd. [1] - The company offers a digital medical education platform called Medical MOOC, which combines advanced medical education concepts with modern internet technology, providing accessible and continuous learning opportunities for healthcare professionals [1] - Zhongchao Medical focuses on three main business segments: 1. Medical MOOC, 2. Sunshine Health Classroom, 3. Zhongxun Patient Assistance [1]

Core Viewpoint - Zhongchao Medical (ZCMD) experienced a stock price increase of 6.52% on August 19, reaching $0.98 per share, with a total market capitalization of $24.7488 million [1] Financial Performance - As of December 31, 2024, Zhongchao Medical reported total revenue of $15.8648 million, a year-over-year decrease of 18.37% [1] - The company recorded a net profit attributable to shareholders of -$0.6432 million, which represents a year-over-year increase of 94.33% [1] Company Overview - Zhongchao Medical is a foreign holding company registered in the Cayman Islands on April 16, 2019, and operates through its domestic subsidiary, Zhongchao Medical Technology (Shanghai) Co., Ltd. [1] - The subsidiary's platform, Medical MOOC, integrates advanced medical education concepts with modern internet technology, providing accessible and continuous learning opportunities for healthcare professionals [1] - Zhongchao Medical focuses on three main business segments: 1. Medical MOOC, 2. Sunshine Health Classroom, 3. Zhongxun Patient Assistance [1]